Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | AGER | Q15109 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448035 | 0.85 | NAPRT (0.58) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL4290255 | 0.85 | NAPRT (0.58) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL3463758 | 0.84 | NAPRT (0.56) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL10427732 | 0.79 | NAPRT (0.51) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL3078744 | 0.79 | NAPRT (0.38) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL16967455 | 0.78 | NAPRT (0.50) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL21121863 | 0.77 | KDM4E (0.41) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL4117490 | 0.75 | KDM4E (0.39) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL28694564 | 0.74 | NAPRT (0.46) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL21119052 | 0.73 | ALDH1A1 (0.51) | NAPRTKDM4ETDP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166174-A1 | COMPOUNDS MODULATING C-KIT AND C-FMS ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. | 2011-07-07 | — | — | US | disclosed |
| US-7846941-B2 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-1885723-A2 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007013896-A2 | PYRROL (2,3-B) PYRIDINE DERIVATIVES PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166174-A1 | COMPOUNDS MODULATING C-KIT AND C-FMS ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | NAPRT 1994/4885KDM4E 2130/4885TDP1 3273/4885 |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | KIT, FLT3, FLT1 | NAPRT 1994/4885KDM4E 2130/4885TDP1 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.